1. Baglin T, Barrowcliffe TW, Cohen A, Greaves M (2006) Guidelines on the use and monitoring of heparin. Br J Haematol 133:19–34
2. Kumano O, Akatsuchi K, Amiral J (2021) Updates on anticoagulation and laboratory tools for therapy monitoring of heparin, vitamin K antagonists and direct oral anticoagulants. Biomedicine 9:264
3. Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e24S–e43S
4. Johnson PN, Benefield EC, Bui PY, Gausman JN, Marlar RA, Gessouroun MR (2013) Fondaparinux monitoring: need for a local Fondaparinux-calibrated anti-F actor Xa assay. J Pediatr Pharmacol Ther 18:318–319
5. Lehman CM, Frank EL (2009) Laboratory monitoring of heparin therapy: partial thromboplastin time or anti-Xa assay? Lab Med 40:47–51